Quince Therapeutics shares surge 29.21% intraday following positive safety review for pivotal NEAT Phase 3 trial.

Quince Therapeutics (QNCX) surged 29.21% intraday following a positive safety review of its pivotal Phase 3 NEAT trial, a key catalyst expected to deliver topline results in Q1 2026. The rally, part of a seven-day 59% gain, reflects growing investor confidence in the trial’s potential to advance the company’s rare disease therapy toward regulatory approval. The stock’s momentum aligns with improved financial discipline, a focused pipeline targeting unmet medical needs, and strong outperformance against the S&P 500. The safety review clearance, combined with narrowing operating losses and a $125M market cap, has positioned QNCX as an asymmetric biotech opportunity, attracting capital amid anticipation of a transformative data readout.